The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | FS118 shows activity in patients with R/R DLBCL post-CAR-T: findings from a Phase II trial
Jean-Marie Michot, MD, Gustave Roussy Institute, Paris, France, comments on the results of an open-label Phase II study of FS118, a LAG-3/PD-L1 bispecific antibody, in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), particularly those post-CAR-T treatment. Dr Michot notes that the treatment showed a 20% response rate, with no elevated rates of immune-related adverse events. This finding suggests that FS118 may be a viable option for this challenging patient population, where current treatments are limited. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So, FS118 was a treatment for patients relapsed or refractory with diffuse large B-cell lymphoma. And this treatment was investigated in a Phase II study, including 10 patients treated, especially in the context of relapsed post-CAR-T treatment. So the study was given for a population of patients relapsed refractory, at least two prior lines of treatment, and we included 10 patients in this cohort, and the result was presented at the ASH meeting...
So, FS118 was a treatment for patients relapsed or refractory with diffuse large B-cell lymphoma. And this treatment was investigated in a Phase II study, including 10 patients treated, especially in the context of relapsed post-CAR-T treatment. So the study was given for a population of patients relapsed refractory, at least two prior lines of treatment, and we included 10 patients in this cohort, and the result was presented at the ASH meeting. We see that the variability of treatment was very fine. We do not see any significant elevated rates of immune-related adverse events. And interestingly, we see two patients with response to the treatment with ongoing response at the last cut-off date of the analysis. So it was 20% of response rate. So the population is very small. It’s difficult to say with a small proportion of patients, but we see activity for this population of patients, especially relapsed refractory post-CAR-T. There is no standard of care for this population of treatment and immune checkpoint inhibitor could be an option to be investigated for such patients because there is no today immune checkpoint in place for diffuse large B-cell lymphoma and especially for relapsed refractory diffuse large B-cell lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Institute Gustave Roussy: Current Employment; Curio Sciences: Consultancy; Regeneron Pharmaceuticals, Inc.: Honoraria; Gilead: Consultancy.
